| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies | Company's Home Page |
| Genentech, Inc. |
| 1 DNA Way, South San Francisco, CA 94080 * (650) 225-1000 |
| Business Description | The company is a leading biotechnology company that uses human genetic information to discover, develop, manufacture and market human pharmaceuticals for significant unmet medical needs. |
| Offering Information Company has | ||||
| Trading As | DNA (NYSE) | Industry | Pharmaceutical (SIC 2834) | |
| Type of Stock Offered | Common Shares | Filing Date | 06/14/1999 | |
| Domestic Shares Offered | 20,000,000 | Offer Date | 07/19/1999 | |
| Foreign Shares Offered | 0 | Filing Range | $85.00 - $95.00 | |
| Company Shares | 0 | Offer Price | $97.00 | |
| Selling Shrhldrs Shares | 20,000,000 | Gross Spread | $2.425 | |
| Gross Proceeds | $1,940,000,000 | Selling | $1.455 | |
| Expenses | - - | Reallowance | $0.100 | |
| Post-IPO Shares | 127,298,588 | Employees | - - | |
| Spun out from: | Roche Holdings, Inc. | |||
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| BancBoston Robertson Stephens | Co-manager | (415) 989-8500 |
| Goldman, Sachs & Co. | Co-manager | (212) 902-5959 |
| Merrill Lynch & Co. | Co-manager | (212) 449-4600 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-4290 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1996 | 12/31/1997 | 12/31/1998 | 06/30/1998 | 06/30/1999 | ||
| Revenues | - | - | 968.700 | 1,016.700 | 1,150.900 | 532.700 | 717.500 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | 118.300 | 129.000 | 181.900 | 81.400 | -908.800 |
| E.P.S | - | - | 0.980 | 1.050 | 1.450 | 0.650 | -7.090 |
| Revenue Growth (%) | - | - | 4.96 | 13.200 | 34.69 | ||
| Net Income Growth (%) | - | - | 9.04 | 41.01 | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | 12.21 | 12.69 | 15.81 | - | 15.28 |
| Cash Flow - Oper. | 349.90 | - | - | ||||
| Cash Flow - Inv. | -421.10 | - | - | ||||
| Cash Flow - Fin. | 107.94 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 03/31/1999 | Financial Ratios | ||||
| Total Assets | 2,926.10 | Current Assets | - | Current Ratio | - |
| Total Liab. | 536.40 | Current Liab. | - | Debt Ratio | 18.33% |
| Total Equity | 2,389.70 | Working Cap. | 942.60 | Debt to Equity Ratio | 0.22 |
| Cash | 1,662.50 | Return on Assets | 6.22% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be distributed to selling shareholder. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Davis, Polk & Wardwell |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Registrar/Transfer Agent | EquiServe |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |